BRAF

chop down cut tree chainsaw ax

Biotech

C4T halts BRAF degrader work to save cash for cemsidomide

C4 Therapeutics is ending work on its clinical-stage BRAF degrader program to focus on its IKZF1/3 degraded cemsidomide.

James Waldron May 7, 2025 7:00am

AstraZenecas new Cambridge UK RD center and global HQ - 2nd floor

AZ uses struggling cancer drug to gain insight into resistance

May 2, 2019 11:25am